Secondary tumors of the ovary account for 10-25% of all ovarian malignancies. The most common tumors that give rise to ovarian metastases include breast, colorectal, endometrial, stomach, and appendix cancer. The correct diagnosis of secondary ovarian tumors may be challenging as they are not infrequently misdiagnosed as primary ovarian cancer, particularly in the case of mucinous adenocarcinomas. The distinction from the latter is essential, as it requires different treatment. Immunohistochemistry plays an important role in distinguishing primary ovarian tumors from extra-ovarian metastases and, furthermore, may suggest the primary tumor site. Despite extensive study, some cases remain equivocal even after assessing a broad spectrum of antigens. Therefore, gene expression profiling represents an approach able to further discriminate equivocal findings, and one that has been proven effective in determining the origin of cancer of unknown primary site. The available data concerning secondary ovarian tumors is rather limited owing to the relative heterogeneity of this group and the practical absence of any prospective trials. However, several intriguing questions are encountered in daily practice, including rational diagnostic workup, the role of cytoreductive surgery, and consequent adjuvant chemotherapy. This review seeks to address these issues comprehensively and summarize current knowledge on the epidemiology, pathogenesis, and management of secondary ovarian tumors, including further discussion on the different pathways of metastatisation, metastatic organotropism, and their possible molecular mechanisms.

Department of Obstetrics and Gynecology Faculty of Medicine and University Hospital in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital in Hradec Králové Charles University Sokolská 581 500 05 Hradec Králové Czech Republic

The Fingerland Department of Pathology Faculty of Medicine and University Hospital in Hradec Králové Charles University Hradec Králové Czech Republic

Zobrazit více v PubMed

Krukenberg FE. Über Das Fibrosarcoma ovarii mucocellulare (carcinomatodes) Arch Gynäkol. 1896;50:287–321. doi: 10.1007/BF01700650. DOI

Kraus E. Über das zustandekommen der krebsmetastasen im ovarium bei primärem kerbs eines anderen bauchorgans. Monatsschr Geburtsh Gynakol. 1901;14:1–30.

Woodruff JD, Novak ER. The Krukenberg tumor: study of 48 cases from the ovarian tumor registry. Obstet Gynecol. 1960;15:351–360. PubMed

Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol. 2006;30(3):277–299. doi: 10.1097/01.pas.0000190787.85024.cb. PubMed DOI

Young RH. From krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the krukenberg tumor. Adv Anat Pathol. 2006;13(5):205–227. doi: 10.1097/01.pap.0000213038.85704.e4. PubMed DOI

Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med. 2006;130(11):1725–1730. PubMed

Fujiwara K, Ohishi Y, Koike H, Sawada S, Moriya T, Kohno I. Clinical implications of metastases to the ovary. Gynecol Oncol. 1995;59(1):124–128. doi: 10.1006/gyno.1995.1278. PubMed DOI

Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93(1):87–91. doi: 10.1016/j.ygyno.2003.12.039. PubMed DOI

Petru E, Pickel H, Heydarfadai M, Lahousen M, Haas J, Schaider H, Tamussino K. Nongenital cancers metastatic to the ovary. Gynecol Oncol. 1992;44(1):83–86. doi: 10.1016/0090-8258(92)90017-D. PubMed DOI

Ayhan A, Guvenal T, Salman MC, Ozyuncu O, Sakinci M, Basaran M. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol. 2005;98(2):235–241. doi: 10.1016/j.ygyno.2005.05.028. PubMed DOI

Lee SJ, Bae JH, Lee AW, Tong SY, Park YG, Park JS. Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci. 2009;24(1):114–119. doi: 10.3346/jkms.2009.24.1.114. PubMed DOI PMC

Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, Dastamani C, Bakalianou K, Liapis A, Hassiakos D, Fotiou S. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet. 2011;284(5):1283–1288. doi: 10.1007/s00404-011-1847-4. PubMed DOI

Alvarado-Cabrero I, Rodriguez-Gomez A, Castelan-Pedraza J, Valencia-Cedillo R. Metastatic ovarian tumors: a clinicopathologic study of 150 cases. Anal Quant Cytopathol Histopathol. 2013;35(5):241–248. PubMed

Bruls J, Simons M, Overbeek LI, Bulten J, Massuger LF, Nagtegaal ID. A national population-based study provides insight in the origin of malignancies metastatic to the ovary. Virchows Arch. 2015;467(1):79–86. doi: 10.1007/s00428-015-1771-2. PubMed DOI PMC

de Waal YR, Thomas CM, Oei AL, Sweep FC, Massuger LF. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer. 2009;19(7):1160–1165. doi: 10.1111/IGC.0b013e3181b33cce. PubMed DOI

Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, Bae DS. The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):97–101. doi: 10.1016/j.ejogrb.2009.11.011. PubMed DOI

Yada-Hashimoto N, Yamamoto T, Kamiura S, Seino H, Ohira H, Sawai K, Kimura T, Saji F. Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol. 2003;89(2):314–317. doi: 10.1016/S0090-8258(03)00075-1. PubMed DOI

Demopoulos RI, Touger L, Dubin N. Secondary ovarian carcinoma: a clinical and pathological evaluation. Int J Gynecol Pathol. 1987;6(2):166–175. doi: 10.1097/00004347-198706000-00008. PubMed DOI

Skirnisdottir I, Garmo H, Holmberg L. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990–2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol. 2007;105(1):166–171. doi: 10.1016/j.ygyno.2006.11.005. PubMed DOI

Miller BE, Pittman B, Wan JY, Fleming M. Colon cancer with metastasis to the ovary at time of initial diagnosis. Gynecol Oncol. 1997;66(3):368–371. doi: 10.1006/gyno.1997.4811. PubMed DOI

Kikkawa F, Shibata K, Ino K, Nomura S, Kajiyama H, Suzuki T, Kawai M, Mizutani S. Preoperative findings in non-gynecologic carcinomas metastasizing to the ovaries. Gynecol Obstet Invest. 2002;54(4):221–227. doi: 10.1159/000068388. PubMed DOI

Sal V, Demirkiran F, Topuz S, Kahramanoglu I, Yalcin I, Bese T, Sozen H, Tokgozoglu N, Salihoglu Y, Turan H, Iyibozkurt C, Kolomuc T, Sofiyeva N, Berkman S, Arvas M. Surgical treatment of metastatic ovarian tumors from extragenital primary sites. Int J Gynecol Cancer. 2016;26(4):688–696. doi: 10.1097/IGC.0000000000000673. PubMed DOI

Ganesh K, Shah RH. Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer. 2017;123(7):1134–1143. doi: 10.1002/cncr.30424. PubMed DOI PMC

Shah B, Tang W, Karn S. An Up-to-Date Understanding of the “Krukenberg Tumor” Mechanism. Adv Reprod Sci. 2016;4:31–36. doi: 10.4236/arsci.2016.42005. DOI

Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7(11):925–934. doi: 10.1016/S1470-2045(06)70939-1. PubMed DOI

Yamanishi Y, Koshiyama M, Ohnaka M, Ueda M, Ukita S, Hishikawa K, Nagura M, Kim T, Hirose M, Ozasa H, Shirase T. Pathways of metastases from primary organs to the ovaries. Obstet Gynecol Int. 2011;2011:612817. doi: 10.1155/2011/612817. PubMed DOI PMC

Kakushima N, Kamoshida T, Hirai S, Hotta S, Hirayama T, Yamada J, Ueda K, Sato M, Okumura M, Shimokama T, Oka Y. Early gastric cancer with Krukenberg tumor and review of cases of intramucosal gastric cancers with Krukenberg tumor. J Gastroenterol. 2003;38(12):1176–1180. doi: 10.1007/s00535-003-1227-3. PubMed DOI

Asbun HJ, Hughes KS. Management of recurrent and metastatic colorectal carcinoma. Surg Clin North Am. 1993;73(1):145–166. doi: 10.1016/S0039-6109(16)45934-7. PubMed DOI

Kall SL, Koblinski JE. Genes that mediate metastasis organotropism. Austin: Landes Bioscience; 2013. Metastatic cancer: clinical and biological perspectives.

Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–152. doi: 10.1038/nature06487. PubMed DOI PMC

Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, Sezhiyan A, Pfeifer J, Li YF, Hua X, Wang Y, Yang P, You M. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012;33(5):1046–1054. doi: 10.1093/carcin/bgs100. PubMed DOI PMC

Lorusso G, Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol. 2012;22(3):226–233. doi: 10.1016/j.semcancer.2012.03.007. PubMed DOI

Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2012;132(2):523–535. doi: 10.1007/s10549-011-1619-7. PubMed DOI PMC

Crobach S, Ruano D, van Eijk R, Schrumpf M, Fleuren G, van Wezel T, Morreau H. Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: identification of driver and passenger mutations. J Pathol Clin Res. 2016;2(3):166–174. doi: 10.1002/cjp2.45. PubMed DOI PMC

Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26(25):4160–4165. doi: 10.1200/JCO.2008.16.4814. PubMed DOI PMC

Papakonstantinou E, Liapis A, Kairi-Vassilatou E, Iavazzo C, Kleanthis CK, Kondi-Pafiti A. Virilizing ovarian Krukenberg tumor in a 27-year-old pregnant woman. A case report and literature review. Eur J Gynaecol Oncol. 2011;32(3):331–333. PubMed

Bruchim I, Ben-Harim Z, Piura E, Tepper R, Fishman A. Preoperative clinical and radiological features of metastatic ovarian tumors. Arch Gynecol Obstet. 2013;288(3):615–619. doi: 10.1007/s00404-013-2776-1. PubMed DOI

McCluggage WG. The value of immunohistochemistry as a diagnostic aid in ovarian neoplasia: a review. AJSP. 2006;11(1):31–37.

Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. Gynecol Oncol. 2006;101(1):97–101. doi: 10.1016/j.ygyno.2005.09.046. PubMed DOI

Varadhachary GR. Carcinoma of unknown primary origin. Gastrointest Cancer Res. 2007;1(6):229–235. PubMed PMC

Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v133–v138. doi: 10.1093/annonc/mdv305. PubMed DOI

National Comprehensive Cancer Network (2016) Occult primary (cancer of unknown primary [CUP]) (version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf. Accessed 1 August 2016

Brown DL, Zou KH, Tempany CM, Frates MC, Silverman SG, McNeil BJ, Kurtz AB. Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study. Radiology. 2001;219(1):213–218. doi: 10.1148/radiology.219.1.r01ap28213. PubMed DOI

Willmott F, Allouni KA, Rockall A. Radiological manifestations of metastasis to the ovary. J Clin Pathol. 2012;65(7):585–590. doi: 10.1136/jclinpath-2011-200390. PubMed DOI

Park HL, Yoo Ie R, O JH, Han EJ, Kim SH. F-18 FDG PET/CT findings of metastatic ovarian tumors from gastrointestinal tract origin. J Cancer Res Clin Oncol. 2015;141(10):1871–1878. doi: 10.1007/s00432-015-1978-2. PubMed DOI PMC

Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27(Suppl 1):S215–229. doi: 10.1148/rg.27si075517. PubMed DOI

Kwee TC, Basu S, Alavi A. PET and PET/CT for unknown primary tumors. Methods Mol Biol. 2011;727:317–333. doi: 10.1007/978-1-61779-062-1_17. PubMed DOI

Moller AK, Loft A, Berthelsen AK, Pedersen KD, Graff J, Christensen CB, Costa JC, Skovgaard LT, Perell K, Petersen BL, Daugaard G. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist. 2012;17(9):1146–1154. doi: 10.1634/theoncologist.2011-0449. PubMed DOI PMC

Pepin K, del Carmen M, Brown A, Dizon DS. CA 125 and epithelial ovarian cancer: role in screening, diagnosis, and surveillance. Am J Hematol Oncol. 2014;10(6):22–29.

Yedema CA, Kenemans P, Wobbes T, Thomas CM, Bon GG, Mulder C, Voorhorst FJ, Verstraeten AA, van Kamp GJ, Hilgers J. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour biol. 1992;13(1–2):18–26. doi: 10.1159/000217748. PubMed DOI

Pavlidis N, Kalef-Ezra J, Briassoulis E, Skarlos D, Kosmidis P, Saferiadis K, Bairaktari E, Bafaloukos D, Maravegias A, Theoharis D, et al. Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol. 1994;22(3):162–167. doi: 10.1002/mpo.2950220303. PubMed DOI

Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. The Lancet. 2012;379(9824):1428–1435. doi: 10.1016/S0140-6736(11)61178-1. PubMed DOI

Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol. 2008;32(1):128–138. doi: 10.1097/PAS.0b013e3180690d2d. PubMed DOI

Kurman RJ, International Agency for Research on Cancer. World Health Organization . WHO classification of tumours of female reproductive organs. World Health Organization classification of tumours. 4. Lyon: International Agency for Research on Cancer; 2014.

Ulbright TM, Roth LM, Stehman FB. Secondary ovarian neoplasia. A clinicopathologic study of 35 cases. Cancer. 1984;53(5):1164–1174. doi: 10.1002/1097-0142(19840301)53:5<1164::AID-CNCR2820530523>3.0.CO;2-4. PubMed DOI

Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23(2):110–118. doi: 10.1097/00004347-200404000-00004. PubMed DOI

Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med. 2008;132(3):402–423. PubMed

Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol. 1999;52(4):283–290. doi: 10.1136/jcp.52.4.283. PubMed DOI PMC

Prat J. Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Modern Pathol. 2005;18(Suppl 2):S99–S111. doi: 10.1038/modpathol.3800312. PubMed DOI

Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138(1):57–64. doi: 10.1309/AJCP5UAFMSA9ZQBZ. PubMed DOI

Tornos C, Soslow R, Chen S, Akram M, Hummer AJ, Abu-Rustum N, Norton L, Tan LK. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29(11):1482–1489. doi: 10.1097/01.pas.0000176429.88702.36. PubMed DOI

Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135(1):92–109. PubMed

Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Modern Pathol. 1996;9(4):426–429. PubMed

Charpin C, Bhan AK, Zurawski VR, Jr, Scully RE. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies. Int J Gynecol Pathol. 1982;1(3):231–245. doi: 10.1097/00004347-198203000-00001. PubMed DOI

Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol. 2000;31(6):672–677. doi: 10.1053/hupa.2000.6799. PubMed DOI

Chou YY, Jeng YM, Kao HL, Chen T, Mao TL, Lin MC. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology. 2003;43(2):151–156. doi: 10.1046/j.1365-2559.2003.01687.x. PubMed DOI

Groisman GM, Meir A, Sabo E. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol. 2004;23(1):52–57. doi: 10.1097/01.pgp.0000101141.31270.a0. PubMed DOI

Okamoto T, Matsumura N, Mandai M, Oura T, Yamanishi Y, Horiuchi A, Hamanishi J, Baba T, Koshiyama M, Shiozawa T, Konishi I. Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1. Modern Pathol. 2011;24(2):267–276. doi: 10.1038/modpathol.2010.204. PubMed DOI

Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymańska-Pasternak J, Górski B, Menkiszak J, Rzepka-Górska I, Lubiński J. Hereditary breast and ovarian cancer. Hered Cancer Clin Pract. 2008;6(2):1–11. doi: 10.1186/1897-4287-6-2-88. PubMed DOI PMC

Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127(1):103–113. doi: 10.1309/TDP92PQLDE2HLEET. PubMed DOI

Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32(10):1566–1571. doi: 10.1097/PAS.0b013e31816d71ad. PubMed DOI

van der Post RS, Bult P, Vogelaar IP, Ligtenberg MJ, Hoogerbrugge N, van Krieken JH. HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Arch. 2014;464(6):673–679. doi: 10.1007/s00428-014-1574-x. PubMed DOI

Cameron RI, Ashe P, O’Rourke DM, Foster H, McCluggage WG. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2003;22(3):272–276. doi: 10.1097/01.PGP.0000071044.12278.43. PubMed DOI

Masood S, Rhatigan RM, Wilkinson EW, Barwick KW, Wilson WJ. Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. Cancer. 1993;72(2):511–518. doi: 10.1002/1097-0142(19930715)72:2<511::AID-CNCR2820720230>3.0.CO;2-Q. PubMed DOI

Ghandour FA, Attanoos R, Nahar K, Gee JW, Bigrigg A, Ismail SM. Immunocytochemical localization of oestrogen and progesterone receptors in primary adenocarcinoma of the cervix. Histopathology. 1994;24(1):49–55. doi: 10.1111/j.1365-2559.1994.tb01270.x. PubMed DOI

Negri G, Egarter-Vigl E, Kasal A, Romano F, Haitel A, Mian C. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol. 2003;27(2):187–193. doi: 10.1097/00000478-200302000-00006. PubMed DOI

Zubovits J, Buzney E, Yu L, Duncan LM. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol. 2004;35(2):217–223. doi: 10.1016/j.humpath.2003.09.019. PubMed DOI

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. Mol Diagn Ther. 2015;19(2):91–97. doi: 10.1007/s40291-015-0133-8. PubMed DOI

Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, Erlander MG, Highsmith WE, Dry SM, Brachtel EF. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18(14):3952–3960. doi: 10.1158/1078-0432.CCR-12-0920. PubMed DOI

Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser M, Huszar M, Fogt F, Ashkenazi K, Sanden M, Goren E, Dromi N, Zion O, Burnstein I, Chajut A, Spector Y, Aharonov R. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 2012;17(6):801–812. doi: 10.1634/theoncologist.2011-0466. PubMed DOI PMC

Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31(2):217–223. doi: 10.1200/JCO.2012.43.3755. PubMed DOI

Geraldine M, Agnes L, WVdW Agnes, Gedske D, Carmen B, Nicolas P, Loic C, Djelila A, Bruno C, Stephane C, Marine G-G, Yacine M, Cristian M, Elodie V, Isabelle B, Fanny W, Catherine AS, Karim F. GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown primary (CUP) J Clin Oncol. 2014;32(15_suppl):TPS11134TPS11134.

Meyniel JP, Cottu PH, Decraene C, Stern MH, Couturier J, Lebigot I, Nicolas A, Weber N, Fourchotte V, Alran S, Rapinat A, Gentien D, Roman-Roman S, Mignot L, Sastre-Garau X. A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. BMC Cancer. 2010;10:222. doi: 10.1186/1471-2407-10-222. PubMed DOI PMC

Mhawech-Fauceglia P, Rai H, Nowak N, Cheney RT, Rodabaugh K, Lele S, Odunsi K. The use of array-based comparative genomic hybridization (a-CGH) to distinguish metastatic from primary synchronous carcinomas of the ovary and the uterus. Histopathology. 2008;53(4):490–495. doi: 10.1111/j.1365-2559.2008.03107.x. PubMed DOI

Jiang R, Tang J, Cheng X, Zang RY. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol. 2009;35(1):92–97. doi: 10.1016/j.ejso.2008.05.006. PubMed DOI

Rayson D, Bouttell E, Whiston F, Stitt L. Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol. 2000;75(3):186–192. doi: 10.1002/1096-9098(200011)75:3<186::AID-JSO6>3.0.CO;2-S. PubMed DOI

McCormick CC, Giuntoli RL, 2nd, Gardner GJ, Schulick RD, Judson K, Ronnett BM, Vang R, Bristow RE. The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol. 2007;105(3):791–795. doi: 10.1016/j.ygyno.2007.02.025. PubMed DOI

Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol. 2004;94(2):477–482. doi: 10.1016/j.ygyno.2004.05.007. PubMed DOI

Lu LC, Shao YY, Hsu CH, Hsu C, Cheng WF, Lin YL, Cheng AL, Yeh KH. Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res. 2012;32(8):3397–3401. PubMed

Rosa F, Marrelli D, Morgagni P, Cipollari C, Vittimberga G, Framarini M, Cozzaglio L, Pedrazzani C, Berardi S, Baiocchi GL, Roviello F, Portolani N, de Manzoni G, Costamagna G, Doglietto GB, Pacelli F. Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg. 2016;40(4):921–928. doi: 10.1007/s00268-015-3326-8. PubMed DOI

Savey L, Lasser P, Castaigne D, Michel G, Bognel C, Colau JC. Krukenberg tumors. Analysis of a series of 28 cases. J Chir. 1996;133(9–10):427–431. PubMed

Mrad K, Morice P, Fabre A, Pautier P, Lhomme C, Duvillard P, Sabourin JC. Krukenberg tumor: a clinico-pathological study of 15 cases. Ann Pathol. 2000;20(3):202–206. PubMed

Abu-Rustum NR, Aghajanian CA, Venkatraman ES, Feroz F, Barakat RR. Metastatic breast carcinoma to the abdomen and pelvis. Gynecol Oncol. 1997;66(1):41–44. doi: 10.1006/gyno.1997.4720. PubMed DOI

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Nat Cancer Inst. 2014;106(6):dju124. doi: 10.1093/jnci/dju124. PubMed DOI

Erroi F, Scarpa M, Angriman I, Cecchetto A, Pasetto L, Mollica E, Bettiol M, Ruffolo C, Polese L, Cillo U, D’Amico DF. Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy. J Surg Oncol. 2007;96(2):113–117. doi: 10.1002/jso.20803. PubMed DOI

Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG, Barbera MA, Pantaleo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J Gastroenterol. 2016;22(2):519–533. doi: 10.3748/wjg.v22.i2.519. PubMed DOI PMC

Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, Tu D, Sargeant AM, A. F. Fluorouracil (FU) plus leucovorin (I-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC/CTG/GIVIO) randomized trial. Proc Am Clin Oncol. 2002;21:149a.

Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24(31):4976–4982. doi: 10.1200/JCO.2006.06.8353. PubMed DOI

Kim SY, Kim HJ, Hong YS, Jung KH, Park JW, Choi HS, Oh JH, Park SJ, Kim SH, Nam BH, Chang HJ, Kim DY. Resected colorectal liver metastases: does the survival differ according to postoperative chemotherapy regimen? J Surg Oncol. 2009;100(8):713–718. doi: 10.1002/jso.21403. PubMed DOI

Clinicopathological Characteristics and Prognostic Factors in Ovarian Metastases from Right- and Left-Sided Colorectal Cancer